Analysts Offer Insights on Healthcare Companies: Humana (HUM), Tenet Healthcare (THC) and Stoke Therapeutics (STOK)
Analysts have been eager to weigh in on the Healthcare sector with new ratings on Humana (HUM – Research Report), Tenet Healthcare (THC – Research Report) and Stoke Therapeutics (STOK – Research Report).
Valentine's Day Sale - 70% Off
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Humana (HUM)
Barclays analyst Andrew Mok CFA maintained a Hold rating on Humana today and set a price target of $245.00. The company’s shares closed last Wednesday at $175.40.
According to TipRanks.com, CFA is a 1-star analyst with an average return of
The word on The Street in general, suggests a Hold analyst consensus rating for Humana with a $263.40 average price target, representing a 54.1% upside. In a report released today, RBC Capital also downgraded the stock to Hold with a $189.00 price target.
See today’s best-performing stocks on TipRanks >>
Tenet Healthcare (THC)
KeyBanc analyst Matthew Gillmor CFA maintained a Buy rating on Tenet Healthcare today and set a price target of $250.00. The company’s shares closed last Wednesday at $226.35.
According to TipRanks.com, CFA has currently 0 stars on a ranking scale of 0-5 stars, with an average return of
Currently, the analyst consensus on Tenet Healthcare is a Strong Buy with an average price target of $244.80, representing a 30.0% upside. In a report issued on February 2, UBS also maintained a Buy rating on the stock with a $260.00 price target.
Stoke Therapeutics (STOK)
In a report released yesterday, Thomas Shrader from BTIG maintained a Buy rating on Stoke Therapeutics, with a price target of $39.00. The company’s shares closed last Wednesday at $32.22.
According to TipRanks.com, Shrader is a 4-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Stoke Therapeutics with a $40.13 average price target, representing a 23.5% upside. In a report issued on February 5, Guggenheim also initiated coverage with a Buy rating on the stock with a $60.00 price target.
